- Home
- EML vs INZY Comparison
EML vs INZY Comparison
Compare EML & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- INZY
- Stock Information
- Founded
- EML 1858
- INZY 2015
- Country
- EML United States
- INZY United States
- Employees
- EML N/A
- INZY N/A
- Industry
- EML Industrial Machinery/Components
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- INZY Health Care
- Exchange
- EML Nasdaq
- INZY Nasdaq
- Market Cap
- EML 191.3M
- INZY 188.2M
- IPO Year
- EML N/A
- INZY 2020
- Fundamental
- Price
- EML $27.55
- INZY $1.40
- Analyst Decision
- EML
- INZY Strong Buy
- Analyst Count
- EML 0
- INZY 8
- Target Price
- EML N/A
- INZY $17.75
- AVG Volume (30 Days)
- EML 10.2K
- INZY 1.0M
- Earning Date
- EML 03-11-2025
- INZY 03-11-2025
- Dividend Yield
- EML 1.64%
- INZY N/A
- EPS Growth
- EML N/A
- INZY N/A
- EPS
- EML N/A
- INZY N/A
- Revenue
- EML $284,461,286.00
- INZY N/A
- Revenue This Year
- EML N/A
- INZY N/A
- Revenue Next Year
- EML N/A
- INZY N/A
- P/E Ratio
- EML $13.24
- INZY N/A
- Revenue Growth
- EML 7.70
- INZY N/A
- 52 Week Low
- EML $22.63
- INZY $1.24
- 52 Week High
- EML $35.78
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- EML 40.64
- INZY 31.52
- Support Level
- EML $27.50
- INZY $1.35
- Resistance Level
- EML $28.60
- INZY $1.45
- Average True Range (ATR)
- EML 0.85
- INZY 0.12
- MACD
- EML -0.06
- INZY 0.04
- Stochastic Oscillator
- EML 0.00
- INZY 43.42
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.